Vizionfocus Inc.
Vizionfocus Inc. engages in the manufacturing of medical equipment in Taiwan, China, Japan, and the United States. It also manufactures mechanical equipment, optical instruments, and precision instruments; trades internationally; and provides other consulting services. In addition, the company engages in the research and development, design, development, production, and wholesale of contact lense… Read more
Vizionfocus Inc. (4771) - Net Assets
Latest net assets as of September 2025: NT$4.10 Billion TWD
Based on the latest financial reports, Vizionfocus Inc. (4771) has net assets worth NT$4.10 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.53 Billion) and total liabilities (NT$2.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$4.10 Billion |
| % of Total Assets | 62.72% |
| Annual Growth Rate | 31.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 34.16 |
Vizionfocus Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Vizionfocus Inc. 's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vizionfocus Inc. (2020–2024)
The table below shows the annual net assets of Vizionfocus Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.85 Billion | +89.11% |
| 2023-12-31 | NT$2.04 Billion | +0.67% |
| 2022-12-31 | NT$2.02 Billion | +11.79% |
| 2021-12-31 | NT$1.81 Billion | +39.87% |
| 2020-12-31 | NT$1.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vizionfocus Inc. 's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2829.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.01 Billion | 28.55% |
| Common Stock | NT$584.75 Million | 16.55% |
| Other Components | NT$1.94 Billion | 54.90% |
| Total Equity | NT$3.53 Billion | 100.00% |
Vizionfocus Inc. Competitors by Market Cap
The table below lists competitors of Vizionfocus Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Steyr Motors AG
VI:4X0
|
$184.47 Million |
|
Even Construtora e Incorporadora S.A
SA:EVEN3
|
$184.49 Million |
|
460930
KQ:460930
|
$184.51 Million |
|
Ultra Jaya Milk Industry Tbk
JK:ULTJ
|
$184.55 Million |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
$184.40 Million |
|
PERMA-PIPE INTL HLDGS
F:MF3
|
$184.38 Million |
|
Boryung Pharm
KO:003850
|
$184.35 Million |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
$184.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vizionfocus Inc. 's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,787,188,000 to 3,532,735,000, a change of 1,745,547,000 (97.7%).
- Net income of 669,589,000 contributed positively to equity growth.
- Dividend payments of 187,259,000 reduced retained earnings.
- Other factors increased equity by 1,263,217,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$669.59 Million | +18.95% |
| Dividends Paid | NT$187.26 Million | -5.3% |
| Other Changes | NT$1.26 Billion | +35.76% |
| Total Change | NT$- | 97.67% |
Book Value vs Market Value Analysis
This analysis compares Vizionfocus Inc. 's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.26x to 3.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$20.26 | NT$187.50 | x |
| 2021-12-31 | NT$27.41 | NT$187.50 | x |
| 2022-12-31 | NT$30.65 | NT$187.50 | x |
| 2023-12-31 | NT$33.34 | NT$187.50 | x |
| 2024-12-31 | NT$60.04 | NT$187.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vizionfocus Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.30%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.68x
- Recent ROE (18.95%) is below the historical average (20.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 14.46% | 17.12% | 0.39x | 2.16x | NT$45.18 Million |
| 2021 | 16.44% | 16.49% | 0.49x | 2.03x | NT$91.72 Million |
| 2022 | 19.10% | 17.06% | 0.57x | 1.96x | NT$149.16 Million |
| 2023 | 31.46% | 21.86% | 0.58x | 2.50x | NT$383.56 Million |
| 2024 | 18.95% | 22.30% | 0.51x | 1.68x | NT$316.32 Million |
Industry Comparison
This section compares Vizionfocus Inc. 's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,796,147,300
- Average return on equity (ROE) among peers: 10.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vizionfocus Inc. (4771) | NT$4.10 Billion | 14.46% | 0.59x | $184.40 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |